Prevalence of low ankle-brachial index, elevated plasma fibrinogen and CRP across Framingham risk categories: Data from the National Health and Nutrition Examination Survey (NHANES) 1999-2004

Atherosclerosis

Volumn 216, Issue 1, 2011, Pages 174-179

  Dhangana, Rajoo ^a,b,c   Murphy, Timothy P ^a,b   Pencina, Michael J ^d,e   Zafar, Abdul M ^a,b  

^a RHODE ISLAND HOSPITAL   (United States)

^b BROWN UNIVERSITY   (United States)

^c VANDERBILT UNIVERSITY   (United States)

^d BOSTON UNIVERSITY   (United States)

^e Boston University   (United States)

Author keywords

C reactive protein; Cardiac biomarkers; Cardiovascular diseases; Coronary heart disease; Fibrinogen; Framingham risk score; Peripheral vascular disease

Indexed keywords

C REACTIVE PROTEIN; FIBRINOGEN;

ADULT; AGED; ANKLE BRACHIAL INDEX; ARTICLE; BODY MASS; CARDIOVASCULAR DISEASE; FEMALE; FIBRINOGEN BLOOD LEVEL; HEALTH SURVEY; HUMAN; LOW ANKLE BRACHIAL INDEX; MAJOR CLINICAL STUDY; MALE; PHYSICAL EXAMINATION; PREVALENCE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RISK FACTOR;

ADULT; AGED; ANKLE BRACHIAL INDEX; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CARDIOVASCULAR DISEASES; CHI-SQUARE DISTRIBUTION; CROSS-SECTIONAL STUDIES; FEMALE; FIBRINOGEN; HUMANS; MALE; MIDDLE AGED; NUTRITION SURVEYS; PERIPHERAL VASCULAR DISEASES; PREVALENCE; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; UNITED STATES; UP-REGULATION;

EID: 79955530114     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2010.10.021     Document Type: Article

References (32)

1. Anonymous Mortality from coronary heart disease and acute myocardial infarction - United States, 1998. MMWR Morb Mortal Wkly Rep 2001, 50:90-93.
2. Shepherd J., Cobbe S.M., Ford I., et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995, 333:1301-1307.
3. Downs J.R., Clearfield M., Weis S., et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 1998, 279:1615-1622.
4. Grundy S.M., Pasternak R., Greenland P., Smith S., Fuster V. AHA/ACC scientific statement: assessment of cardiovascular risk by use of multiple-risk-factor assessment equations: a statement for healthcare professionals from the American Heart Association and the American College of Cardiology. J Am Coll Cardiol 1999, 34:1348-1359.
5. Anonymous Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002, 106:3143-3421.
6. Khot U.N., Khot M.B., Bajzer C.T., et al. Prevalence of conventional risk factors in patients with coronary heart disease. JAMA 2003, 290:898-904.
7. Greenland P., Knoll M.D., Stamler J., et al. Major risk factors as antecedents of fatal and nonfatal coronary heart disease events. JAMA 2003, 290:891-897.
8. Magnus P., Beaglehole R. The real contribution of the major risk factors to the coronary epidemics: time to end the " only-50%" myth. Arch Intern Med 2001, 161:2657-2660.
9. Brindle P., Emberson J., Lampe F., et al. Predictive accuracy of the Framingham coronary risk score in British men: prospective cohort study. BMJ 2003, 327:1267.
10. Orford J.L., Sesso H.D., Stedman M., et al. A comparison of the Framingham and European Society of Cardiology coronary heart disease risk prediction models in the normative aging study. Am Heart J 2002, 144:95-100.
11. Dhangana R., Murphy T.P., Zafar A.M., et al. Optimal use of Framingham risk scores to identify individuals for intensive medical risk factor modification. Circulation 2009, 120:S423-a. [Abstract 1004].
12. Greenland P., Abrams J., Aurigemma G.P., et al. Prevention Conference V: beyond secondary prevention: identifying the high-risk patient for primary prevention: noninvasive tests of atherosclerotic burden: Writing Group III. Circulation 2000, 101:E16-22.
13. Fowkes F.G., Murray G.D., et al. Ankle brachial index combined with Framingham risk score to predict cardiovascular events and mortality: a meta-analysis. JAMA 2008, 300:197-208. Ankle Brachial Index Collaboration.
14. Danesh J., Lewington S., et al. Plasma fibrinogen level and the risk of major cardiovascular diseases and nonvascular mortality: an individual participant meta-analysis. JAMA 2005, 294:1799-1809. Fibrinogen Studies Collaboration.
15. Montecucco F., Mach F. New evidences for C-reactive protein (CRP) deposits in the arterial intima as a cardiovascular risk factor. Clin Interv Aging 2008, 3:341-349.
16. Shah T., Casas J.P., Cooper J.A., et al. Critical appraisal of CRP measurement for the prediction of coronary heart disease events: new data and systematic review of 31 prospective cohorts. Int J Epidemiol 2009, 38(1):217-231.
17. Beckman J.A., Jaff M.R., Creager M.A. The United States preventive services task force recommendation statement on screening for peripheral arterial disease: more harm than benefit?. Circulation 2006, 114:861-866.
18. Ridker P.M. C-reactive protein and the prediction of cardiovascular events among those at intermediate risk: moving an inflammatory hypothesis toward consensus. J Am Coll Cardiol 2007, 49:2129-2138.
19. Fortmann S.P., Ford E., Criqui M.H., et al. CDC/AHA workshop on markers of inflammation and cardiovascular disease: application to clinical and public health practice: report from the population science discussion group. Circulation 2004, 110:e554-e559.
20. National Center for Health Statistics. National Health and Nutrition Examination Survey: Data Sets and Related Documentation, http://www.cdc.gov/nchs/nhanes/nhanes_questionnaires.htm.
21. Criqui M.H., Langer R.D., Fronek A., et al. Mortality over a period of 10 years in patients with peripheral arterial disease. N Engl J Med 1992, 326:381-386.
22. Maresca G., Di Blasio A., Marchioli R., Di Minno G. Measuring plasma fibrinogen to predict stroke and myocardial infarction: an update. Arterioscler Thromb Vasc Biol 1999, 19:1368-1377.
23. Buckley D.I., Fu R., Freeman M., Rogers K., Helfand M. C-reactive protein as a risk factor for coronary heart disease: a systematic review and meta-analyses for the U.S. Preventive Services Task Force. Ann Intern Med 2009, 151:483-495.
24. National Center for Health Statistics. National Health and Nutrition Examination Survey: Introduction to NHANES, http://www.cdc.gov/nchs/nhanes/about_nhanes.htm.
25. National Center for Health Statistics. National Health and Nutrition Examination Survey: Analysis and Reporting Guideline, http://www.cdc.gov/nchs/data/nhanes/nhanes_03_04/nhanes_analytic_guidelines_dec_2005.pdf.
26. National Center for Health Statistics. National Health and Nutrition Examination Survey: Lower Extremity Ankle Brachial Blood Pressure Index, http://www.cdc.gov/nchs/data/nhanes/nhanes_03_04/LE.pdf.
27. National Center for Health Statistics. National Health and Nutrition Examination Survey: General Information on Laboratory Methodology, http://www.cdc.gov/nchs/data/nhanes/nhanes_03_04/lab_c_generaldoc.pdf.
28. Wilson P.W., D'Agostino R.B., Levy D., et al. Prediction of coronary heart disease using risk factor categories. Circulation 1998, 97:1837-1847.
29. D'Agostino R.B., Vasan R.S., Pencina M.J., et al. General cardiovascular risk profile for use in primary care: the Framingham Heart Study. Circulation 2008, 117:743-753.
30. Zethelius B., Berglund L., Sundstrom J., et al. Use of multiple biomarkers to improve the prediction of death from cardiovascular causes. N Engl J Med 2008, 358:2107-2116.
31. Hlatky M.A., Greenland P., Arnett D.K., et al. American heart association expert panel on subclinical atherosclerotic diseases and emerging risk factors and the stroke council. Criteria for evaluation of novel markers of cardiovascular risk: a scientific statement from the American Heart Association. Circulation 2009, 119:2408-2416.
32. Helfand M., Buckley D.I., Freeman M., et al. Emerging risk factors for coronary heart disease: a summary of systematic reviews conducted for the U.S. Preventive services task force. Ann Intern Med 2009, 151:496-507.